Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

DuPont Pharmaceuticals has introduced efavirenz (Sustiva) at a much higher price than was expected. Since it may spare patients from using a protease inhibitor, and it has a once daily-dosing schedule, efavirenz is considered an attractive alternative. Although the drug appears promising, activists are concerned that this could be the beginning of a price escalation throughout the industry, and therefore could boost the overall cost of therapy. HIV activists attempted to meet with representatives from DuPont to discuss pricing.
 ...
PMID:Sparing the protease for some spoils the price for all. 1136 2

Efavirenz (Sustiva) is a potent anti-HIV medication that is comparable to Indinavir in lowering viral load and elevating CD4+ counts. One negative side effect of efavirenz is that it may cause false positive results on tests for marijuana use. Confirmatory tests can establish the presence of efavirenz rather than marijuana. Tests used in Canada to detect the presence of marijuana are listed.
 ...
PMID:Efavirenz use may cause false positive result for marijuana. 1136 77

At the AIDS Conference in Geneva, reports were presented on new drugs expected to improve treatment of HIV infection, to be useful in combination therapies, and to be less susceptible to viral resistance. Advances in understanding resistance to specific drugs and cross-resistance among drugs were reported. New information was provided for the following treatments: efavirenz (Sustiva), abacavir with AZT/3TC, Nevirapine (Viramune), Hydroxyurea in combination therapy, the use of double protease inhibitors in regimens, and ABT-378 and PNU-140690. Finally, reports showing that resistance testing may predict which drugs may or may not work for a person are discussed.
 ...
PMID:Notes on the International AIDS Conference. 1136 93

The U.S. Food and Drug Administration (FDA) has approved Sustiva (efavirenz) as the first HIV drug to have a once-daily dosing schedule. The drug, developed by DuPont Pharmaceuticals, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and will be used in combination with other anti-HIV drugs for both adult and pediatric patients. Results from clinical trials show that Sustiva reduces plasma viral loads to below quantifiable levels in a majority of treatment naive and experienced individuals in two, three, and four drug combinations. It can be taken with or without food, although high fat meals may interfere with absorption and should be avoided. The drug is generally well tolerated, with the most significant side effects being nervous system related, such as insomnia and dizziness. Mild to moderate skin rashes were also reported in one out of four patients. Women should not become pregnant while taking Sustiva because birth defects have been noted in animal studies. Contact information is provided.
 ...
PMID:FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration. 1136 15

Efavirenz (Sustiva) is the first once-daily dosing anti-HIV drug approved by the Food and Drug Administration. The non-nucleoside reverse transcriptase inhibitor (NNRTI) is highly potent and more convenient than other therapies, and is used to treat HIV-1 in both adults and pediatric patients. It is effective in combination therapy, and patients on efavirenz had fewer side effects than patients on other triple combinations therapies. It remains to be seen if efavirenz will be used in first-line therapy. Some reports show that patients who are taking other drugs that affect the central nervous system suffer additional central nervous system side effects from efavirenz. There are reports of cross-resistance with other drugs in the same class, and limited data that is available on fetal toxicity suggests that women of childbearing age need to be counseled carefully before taking this drug.
 ...
PMID:First once-daily drug simplifies dosing, offers new options in HIV-1 treatment. 1136 67

The Food and Drug Administration (FDA) approved DuPont Pharma's new non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva, DMP-266). Efavirenz has shown promise in trials with over 2000 participants for up to 24 weeks, and early data suggests it may be as effective as protease inhibitors when used in a combination regimen. It is the first anti-HIV drug approved for once-daily dosing. Efavirenz is well tolerated, and the main side effects reported are dizziness, insomnia, abnormal dreams, and skin rash. Efavirenz has been approved for adults and children, but should not be used by pregnant women. Contact information is provided.
 ...
PMID:FDA approves efavirenz. Food and Drug Administration. 1136 87

More than 100 HIV-related groups, including ACT UP, have endorsed the Fair Pricing Consensus Statement, which requires DuPont to reduce the price of its non-nucleoside reverse transcriptase inhibitor (NNRTI) Sustiva. Sustiva costs nearly twice as much as other NNRTIs. This high cost makes it difficult for programs to support the drug and for individuals to afford it.
 ...
PMID:The high cost of fighting HIV. 1136 35

DuPont Pharmaceuticals' Sustiva (efavirenz) was approved by the FDA as the first once-daily- dosing anti-HIV drug. Sustiva is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and should always be used in conjunction with other antiretrovirals. Contact information is provided.
 ...
PMID:Now approved: Sustiva in combination offers patients a new first-line therapy. 1136 40

More antiretroviral drugs are becoming available, increasing potential treatment regimens but also increasing the complexity of HIV treatment. The 4 newest of the 15 available antiretroviral agents are described: efavirenz (Sustiva, EFV), abacavir (Ziagen, ABC), adefovir (Preveon, ADV), and amprenavir (Agenerase, APV). Information on dosing, side effects, and interactions with other drugs is provided.
Hopkins HIV Rep 1999 Jan
PMID:The new drugs and how to use them. 1136 60

Information is provided on efavirenz (Sustiva, formerly DMP-266), including dosage information, resistance and clinical trial results, and pharmacology. Side effects are reviewed, as are interactions with other anti-HIV drugs. Contact information is provided.
Hopkins HIV Rep 1999 Jan
PMID:Product information. 1136 63


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>